Mohsen Soosanabadi1, Reza Mirfakhraie2, Lilit Atanesyan3, Akbar Biglarian4, Fatemeh Aghakhani Moghadam1, Maryam Rahimi1, Farkhondeh Behjati1, Elaheh Keyhani1,5. 1. Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. 2. Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. MRC-Holland BV, Amsterdam, the Netherlands. 4. Department of Biostatistics and Computer Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. 5. Clinical Research Development Center of Rofeideh Rehabilitation Hospital, Tehran, Iran.
Abstract
BACKGROUND: The aim of this study was to assess the usability of multiplex ligation-dependent probe amplification (MLPA) for copy number determination of HER gene family members (ERBB1-4) in invasive breast carcinoma and to explore the association of ERBB1-4 gene copy numbers with clinicopathological characteristics of breast cancer (BC) patients. METHODS: Clinical and immunohistochemical characteristics were assessed in 104 BC patients and the molecular subtype was determined for each tumor sample. Furthermore, HER-2/neu status was assessed by immunohistochemistry (IHC) and equivocal results were confirmed by Fluorescent in situ hybridization (FISH). The copy numbers of ERBB1-4 genes were determined by MLPA. RESULTS: Twenty-five percent of all patients showed ERBB2 gene-amplification by MLPA, whereas 14.4% of cases showed ERBB-2/neu overproduction at the protein level (IHC). Moreover, only 2.9% and 1.9% of patients showed amplification in ERBB1 and ERBB4, respectively. No copy number changes were observed in ERBB3. Our results indicated a significant association between ERBB2 copy number gain and histological grade (p value= 0.01), stage (p value= 0.02), and tumor subtypes (p value= <0.001). In addition, we found MLPA more accurate in assessing HER2 status with 15.4% and 9.6% gene amplification detection in early stages (1, 2A and 2B) and advanced tumor stages (3A, 3B, and 4), respectively, compared to IHC (early stages= 13.5% and advanced stages= 4.7%). CONCLUSION: According to our findings, MLPA is a fast, precise and low-cost technique to detect ERBB2 amplification, especially in advanced tumor stages. However, due to infrequent amplification found in ERBB1 and ERBB4 as well as the lack of amplification in ERBB3, their importance in the prognostic evaluation of BC patients remains controversial.
BACKGROUND: The aim of this study was to assess the usability of multiplex ligation-dependent probe amplification (MLPA) for copy number determination of HER gene family members (ERBB1-4) in invasive breast carcinoma and to explore the association of ERBB1-4 gene copy numbers with clinicopathological characteristics of breast cancer (BC) patients. METHODS: Clinical and immunohistochemical characteristics were assessed in 104 BC patients and the molecular subtype was determined for each tumor sample. Furthermore, HER-2/neu status was assessed by immunohistochemistry (IHC) and equivocal results were confirmed by Fluorescent in situ hybridization (FISH). The copy numbers of ERBB1-4 genes were determined by MLPA. RESULTS: Twenty-five percent of all patients showed ERBB2 gene-amplification by MLPA, whereas 14.4% of cases showed ERBB-2/neu overproduction at the protein level (IHC). Moreover, only 2.9% and 1.9% of patients showed amplification in ERBB1 and ERBB4, respectively. No copy number changes were observed in ERBB3. Our results indicated a significant association between ERBB2 copy number gain and histological grade (p value= 0.01), stage (p value= 0.02), and tumor subtypes (p value= <0.001). In addition, we found MLPA more accurate in assessing HER2 status with 15.4% and 9.6% gene amplification detection in early stages (1, 2A and 2B) and advanced tumor stages (3A, 3B, and 4), respectively, compared to IHC (early stages= 13.5% and advanced stages= 4.7%). CONCLUSION: According to our findings, MLPA is a fast, precise and low-cost technique to detect ERBB2 amplification, especially in advanced tumor stages. However, due to infrequent amplification found in ERBB1 and ERBB4 as well as the lack of amplification in ERBB3, their importance in the prognostic evaluation of BC patients remains controversial.
Entities:
Keywords:
Breast Cancer; Copy number variation; ERBB1-4; IHC; MLPA
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: A Lebeau; D Deimling; C Kaltz; A Sendelhofert; A Iff; B Luthardt; M Untch; U Löhrs Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Edith A Perez; Patrick C Roche; Robert B Jenkins; Carol A Reynolds; Kevin C Halling; James N Ingle; Lester E Wold Journal: Mayo Clin Proc Date: 2002-02 Impact factor: 7.616
Authors: Ivan Bièche; Peter Onody; Sengül Tozlu; Keltouma Driouch; Michel Vidaud; Rosette Lidereau Journal: Int J Cancer Date: 2003-09-20 Impact factor: 7.396
Authors: Sara Ahmed Aglan; Ahmad Mohamad Zaki; Amel Sobhy El Sedfy; Heba Gaber El-Sheredy; Ola Hussein Elgaddar Journal: Rep Biochem Mol Biol Date: 2022-04